Global Genetic Engineering Market size was valued at USD 1,491.6 Million in 2024 and is expected to reach USD 2,917.2 Million by 2033, at a CAGR of 6.74% during the forecast period 2024 – 2033.
Genetic Engineering Market: Overview
The Global Genetic Engineering Market is experiencing robust growth driven by advancements in biopharmaceuticals, gene editing technologies, and expanding applications in agriculture and personalized medicine. Genetic engineering involves manipulating an organism’s genes to create desired traits, such as pest resistance in crops or targeted therapies for diseases.
The market dynamics are primarily influenced by key drivers, including the rising demand for biopharmaceuticals. Genetic engineering enables the production of complex proteins and antibodies used in treating diseases like cancer and diabetes. The market is also bolstered by technological advancements in gene editing tools like CRISPR-Cas9, which offer precise and efficient modifications to genetic sequences.
However, the market faces challenges such as ethical and regulatory concerns associated with altering genetic material. Stringent regulations can slow down product approvals, impacting market growth. Additionally, the high cost of research and development in genetic engineering presents a barrier to entry for many companies.
Despite these challenges, the market presents significant opportunities, especially in agriculture and personalized medicine. Genetically modified crops are increasingly adopted for improving yield and sustainability, while personalized medicine based on genetic makeup is poised to transform disease treatment.
North America leads the global market, driven by established biotechnology and pharmaceutical industries, robust research ecosystems, and favorable regulatory environments. In contrast, the Asia Pacific region is emerging as a rapidly growing market due to increasing investments, government support, and rising awareness of genetic therapies.
The market is segmented by products, devices, techniques, applications, and end-users. Genetic markers and PCR (Polymerase Chain Reaction) are among the dominant segments, reflecting their critical roles in genetic engineering applications. Gene editing techniques, particularly CRISPR-Cas9, are at the forefront due to their precision and versatility.
Biotechnology companies are the primary end-users, heavily invested in genetic engineering for drug development and agricultural biotechnology. Academic and research institutions also drive innovation in genetic engineering techniques.
Recent developments highlight the market’s progress, including positive clinical trial results for CRISPR-based therapies, partnerships for developing disease-resistant crops, and FDA approvals for gene editing therapies targeting genetic disorders.
Report Scope
| Feature of the Report | Details |
| Market Size in 2024 | USD 1,491.6 Million |
| Projected Market Size in 2033 | USD 2,917.2 Million |
| Market Size in 2023 | USD 1,400 Million |
| CAGR Growth Rate | 6.74% CAGR |
| Base Year | 2023 |
| Forecast Period | 2024-2033 |
| Key Segment | By Product, Devices, Techniques, Application, End-User and Region |
| Report Coverage | Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends |
| Regional Scope | North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America |
| Buying Options | Request tailored purchasing options to fulfil your requirements for research. |
CMI has comprehensively analyzed the Genetic Engineering market. The driving forces, restraints, challenges, opportunities, and key trends have been explained in depth to depict an in-depth scenario of the market. Segment wise market size and market share during the forecast period are duly addressed to portray the probable picture of this Genetic Engineering industry.
The competitive landscape includes key innovators, after market service providers, market giants as well and niche players which were studied and analyzed extensively concerning their strengths, weaknesses as well as value addition prospects. In addition, the Report covers key players profiling, market shares, mergers and acquisitions, consequent market fragmentation, new trends and dynamics in partnerships, and emerging business models.
List of the prominent players in the Genetic Engineering Market:
- Merck KGaA (Germany)
- Thermo Fisher Scientific Inc. (US)
- GenScript (China)
- Agilent Technologies (US)
- PerkinElmer (US)
- Lonza (Switzerland)
- Tecan Life Sciences (Switzerland)
- Sangamo Therapeutics (US)
- Editas Medicine (US)
- CRISPR Therapeutics AG (Switzerland)
- Precision Biosciences (US)
- Cellectis S.A. (France)
- Intellia Therapeutics (US)
- Bluebird Bio Inc. (US)
- Regeneron Pharmaceuticals (US)
- AMSBIO (England)
- Creative Biogene (US)
- Synthego Corporation (US)
- Beam Therapeutics Inc. (US)
- Caribou Biosciences Inc. (US)
- Others
The Genetic Engineering Market is segmented as follows:
By Product    Â
- Biochemical
- Genetic Markers
By Devices
- PCR
- Gene Gun
- Gel Assemblies
By Techniques
- Gene Splicing
- Artificial Selection
- Recombinant DNA Technology
- Synthesizing DNA
- Gene Editing
- Other
By Application
- Agriculture
- Medical Industrial
By End-User  Â
- Biotechnology Companies
- Pharmaceutical Manufacturers
- Academic and Research Institutions
- Other
Regional Coverage:
North America
- U.S.
- Canada
- Mexico
- Rest of North America
Europe
- Germany
- France
- U.K.
- Russia
- Italy
- Spain
- Netherlands
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Taiwan
- Rest of Asia Pacific
The Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of the Middle East & Africa
Latin America
- Brazil
- Argentina
- Rest of Latin America